Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 4: 1000 - 1008

DOI: https://doi.org/10.19852/j.cnki.jtcm.2026.04.019

Original Articles

Altered amino acids and acylcarnitines profile in infantile intrahepatic cholestasis liver disease: implication for Traditional Chinese Medicine syndrome differentiation

  • QIU Yanyan ,
  • XIA Yu ,
  • LI Weiwei ,
  • YAN Suqi ,
  • PANG Yusheng
Expand
  • 1 Department of Pediatrics, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530000, China
    2 Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing 210000, China
    3 Department of Integrated Chinese and Western Medicine, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
    4 Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, China
QIU Yanyan and XIA Yu are co-first authors and contributed equally to this work

Received date: 2025-05-13

  Accepted date: 2025-11-25

  Online published: 2026-08-08

Supported by

National Natural Science Foundation of China: Mechanistic Study on Li-Dan-He-Ji's Hepatoprotective Effects Against Cholestasis in Juvenile Rats ia Suppressing Calcium-Sensing Receptor-Mediated Apoptosis(81574024)

Fold

Abstract

OBJECTIVE: To explore the diagnostic efficacy of blood amino acids (AAs) and acylcarnitines (ACs) profiles as metabolic biomarkers for differentiating Traditional Chinese Medicine (TCM) syndromes in infantile intrahepatic cholestatic liver disease (IICLD).

METHODS: Blood samples were collected from a cohort comprising 50 healthy controls and 77 patients diagnosed with IICLD, including 43 cases categorized as cold-damp obstruction and stagnation syndrome (COS) and 34 cases as jaundice due to stasis and accumulation syndrome (JSA) based on TCM diagnostic criteria. Metabolomic analyses targeting AAs and ACs were performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

RESULTS: Compared with the healthy controls group, the IICLD group showed 23 upregulated and 2 downregulated metabolites with a screening threshold of variables of importance in projection (VIP) ≥ 1, fold change (FC) ≥ 1.2 or ≤ 0.83, and P <0.05. Six different metabolites were screened between the COS group and JSA group with a screening threshold of VIP ≥ 1, FC ≥ 1.2 or ≤ 0.83, and P <0.05. Ornithine (Orn), Decanedioy lcarnitine (C10DC), Caproylcarnitine (C6) were identified as potential biomarkers for distinguishing between the two syndromes with VIP > 2, FC ≥ 1.2 or ≤ 0.83 and P <0.05; The areas under the receiver operating characteristic curves (AUC) for these biomarkers were Orn (AUC = 0.7394), C10DC (AUC = 0.7777), and C6 (AUC = 0.686). When the levels of these three biomarkers were combined, the AUC increased to 0.922.

CONCLUSION: Distinct alteration of AAs and ACs profile highlighted the oxidative stress and mitochondrial impairment in IICLD. A combined set of metabolites (Orn+ C10DC+ C6) emerged as valuable biomarker for differentiating between the COS syndrome and JSA syndromes, providing a biochemical basis for syndrome differentiation.

Key words： infant; cholestasis; metabolomics; amino acids; carnitine acyltransferases

Cite this article

QIU Yanyan , XIA Yu , LI Weiwei , YAN Suqi , PANG Yusheng . Altered amino acids and acylcarnitines profile in infantile intrahepatic cholestasis liver disease: implication for Traditional Chinese Medicine syndrome differentiation[J]. Journal of Traditional Chinese Medicine, 2026 , 46(4) : 1000 -1008 . DOI: 10.19852/j.cnki.jtcm.2026.04.019

References

1. Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64: 154-68.
2. Feldman AG, Sokol RJ. Recent developments in diagnostics and treatment of neonatal cholestasis. Semin Pediatr Surg 2020; 29: 150945.
3. Liu Y, Huang ZH. Clinical diagnosis and treatment of cholestatic hepatopathy in infants. J Clin Hepatol 2015; 31: 1218-20.
4. Yi W, Yan SQ, Tang JQ, Ma X, Su MJ, Li H. Effects of Li-Dan-He-Ji on regulating oxidative stress and antagonising infantile cholestatic hepatic fibrosis. Zhong Hua Wei Zhong Bing Ji Jiu Yi Xue 2023; 35: 741-5.
5. Shu J, He Q, Mu J, You SJ, Li YN, Wu XM. Treatment of infantile intrahepatic cholestatic liver disease based on hepatic collateral theory. J Tradit Chin Med 2021; 62: 79-81.
6. Qin H, Zhang LL, Xiong XL, et al. Lidan Heji improves infantile cholestasis hepatopathy through inhibiting calcium-sensing receptor-mediated hepatocyte apoptosis. Front Pharmacol 2020; 11: 156.
7. Lin XX, He Q, Zhang XH, SU WW, Ding ZX. Treatment of low γ-glutamyl transpeptidase type of infantile cholestatic liver disease with liver colla-terals obstruction and damp-heat internal accumulation syndrome by tongluo lidan decoction: 72 cases clinical observation. J Tradit Chin Med 2023; 64: 1248-54.
8. Li Z, Xu C. The fundamental theory of Traditional Chinese Medicine and the consideration in its research strategy. Front Med 2011; 5: 208-11.
9. Ma R. Pediatrics of Traditional Chinese Medicine. Beijing: China Press of Traditional Chinese Medicine, 2016: 240-3.
10. Wang XF, Zheng J. Pediatrics of Traditional Chinese and Western Medicine. Beijing: China Press of Traditional Chinese Medicine, 2016: 53-8.
11. Wu JM, Yan N, Liya T, Fei MA, Lin YT, Zhuo YY. Difference of the gut microbiota of premature ovarian insufficiency in two traditional Chinese syndromes. J Tradit Chin Med 2025; 45: 132-9.
12. Gonzalez-Pena D, Brennan L. Recent advances in the application of metabolomics for nutrition and health. Annu Rev Food Sci Technol 2019; 10: 479-519.
13. Yang Q, Zhang AH, Miao JH, et al. Metabolomics biotechnology, applications, and future trends: a systematic review. RSC Adv 2019; 9: 37245-57.
14. Sha Q, Zhang Z, Li H, Xu Y, Wang J, Du A. Serum metabolomic profile of myasthenia gravis and potential values as biomarkers in disease monitoring. Clinica Chimica Acta 2024; 562: 119873.
15. Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev 2019; 99: 1819-75.
16. Wudy SI, Mittermeier-Klessinger VK, Dunkel A, et al. High-throughput analysis of underivatized amino acids and acylcarnitines in infant serum: a micromethod based on stable isotope dilution targeted HILIC-ESI-MS/MS. J Agric Food Chem 2023; 71: 8633-47.
17. Nambo-Venegas R, Valdez-Vargas C, Cisneros B, et al. Altered plasma acylcarnitines and amino acids profile in spinocerebellar ataxia type 7. Biomolecules 2020; 10: 390.
18. McCann MR, George De la Rosa MV, Rosania GR, Stringer KA. L-carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine. Metabolites 2021; 11: 51.
19. Cynober LA. Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 2002; 18: 761-6.
20. Copple BL, Jaeschke H, Klaassen CD. Oxidative stress and the pathogenesis of cholestasis. Semin Liver Dis 2010; 30: 195-204.
21. Fossdal G, Braadland P, Hov JR, et al. Mitochondrial dysfunction and lipid alterations in primary sclerosing cholangitis. Scand J Gastroenterol 2025; 60: 165-73.
22. Subspecialty Group of Infectious Diseases tSoPCMA, Subspecialty Group of Gastroenterology tSoPCMA, Editorial Board CJoP. Expert consensus on diagnosis and treatment of infantile cholestasis. Chin J Pediatr 2022; 60: 990-7.
23. Dong C, Huang ZH. Diagnosis and differential diagnosis of infantile cholestasis disease. Chin J Appl Clin Pediatr 2018; 33: 1441-7.
24. Gu MY, Yang Y, Sun Y, Shang Y, Hu XS. Guideline for TCM pediatrics clinical diagnosis and treatment·fetal Jaundice (amendment). Zhong Yi Er Ke Za Zhi 2018; 14: 5-9.
25. Mai M, Tonjes A, Kovacs P, Stumvoll M, Fiedler GM, Leichtle AB. Serum levels of acylcarnitines are altered in prediabetic conditions. PLoS One 2013; 8: e82459.
26. Zhang J, Chen Q, Zhang L, et al. Simultaneously quantifying hundreds of acylcarnitines in multiple biological matrices within ten minutes using ultrahigh-performance liquid-chromatography and tandem mass spectrometry. J Pharm Anal 2024; 14: 140-8.
27. McGill MR, Li F, Sharpe MR, et al. Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans. Arch Toxicol 2014; 88: 391-401.
28. Dong R, Ye N, Zhao S, et al. Studies on novel diagnostic and predictive biomarkers of intrahepatic cholestasis of pregnancy through metabolomics and proteomics. Front Immunol 2021; 12: 733225.
29. Ribel-Madsen A, Ribel-Madsen R, Brons C, Newgard CB, Vaag AA, Hellgren LI. Plasma acylcarnitine profiling indicates increased fatty acid oxidation relative to tricarboxylic acid cycle capacity in young, healthy low birth weight men. Physiol Rep 2016; 4: 12977.
30. Levitsky DO, Skulachev VP. Carnitine: the carrier transporting fatty acyls into mitochondria by means of an electrochemical gradient of H+. Biochim Biophys Acta 1972; 275: 33-50.
31. Oono T, Yamasaki T, Zaitsu J, et al. Association of tyrosine with insulin resistance in hepatitis C virus-related chronic liver disease. Hepatol Res 2014; 44: E54-62.
32. Ferreira GK, Scaini G, Carvalho-Silva M, et al. Effect of L-tyrosine in vitro and in vivo on energy metabolism parameters in brain and liver of young rats. Neurotox Res 2013; 23: 327-35.
33. Zhou X, He L, Wu C, Zhang Y, Wu X, Yin Y. Serine alleviates oxidative stress via supporting glutathione synthesis and methionine cycle in mice. Mol Nutr Food Res 2017; 61: 1002.
34. Arya P, Kumar U, Sharma S, et al. Targeted NMR-based serum metabolic profiling of serine, glycine and methionine in acute-on-chronic liver failure patients: possible insights into mitochondrial dysfunction. Anal Sci Adv 2021; 2: 536-45.
35. Zhou X, He L, Zuo S, et al. Serine prevented high-fat diet-induced oxidative stress by activating AMPK and epigenetically modulating the expression of glutathione synthesis-related genes. Biochim Biophys Acta Mol Basis Dis 2018; 1864: 488-98.
36. Zhang J, Li Y. Reflections on research approaches to the material basis of TCM syndromes. Zhong Guo Zhong Yi Ji Chu Yi Xue Za Zhi 2007; 394-5.
37. Li GF. Application of metabolomics in pediatrics of Traditional Chinese Medicine. Zhong Yi Er Ke Za Zhi 2019; 15: 89-92.
38. Liu W, Wei BW, Lu H, Ka YX, Wang W. A multi-omics study on the differences in blood biological characteristics between acute gout patients with damp-heat toxin accumulation syndrome and damp-heat accumulation syndrome. J Tradit Chin Med 2025; 66: 480-91.
39. Wang HH, Zhang FG, Cheng G, et al. Research and practice of the hypothesis of "treatment by syndrome and metabonomics". Chin Gen Pract 2016; 19: 2344-7.
40. McCoin CS, Knotts TA, Adams SH. Acylcarnitines--old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol 2015; 11: 617-25.
41. Schriever SC, Deutsch MJ, Adamski J, Roscher AA, Ensenauer R. Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism. J Nutr Biochem 2013; 24: 824-31.
Options
Outlines

/

〈 〉